Comirnaty, cjepivo protiv COVID-19 (mRNA, modificirani nukleozid)
The medicinal product has been authorised by the European Commission (EC) via centralised procedure in all EU Member States, based on the European Medicines Agency (EMA) experts' opinion.
Name | Comirnaty, cjepivo protiv COVID-19 (mRNA, modificirani nukleozid) |
---|---|
Active Substance | jednolančana glasnička RNA (mRNA) s kapom na 5'kraju, koja kodira protein šiljka (S) virusa SARS-CoV-2, dobivena pomoću in vitro transkripcije iz odgovarajućih predložaka DNA, bez korištenja stanica |
Prescription | na recept |
Type of prescription | neponovljivi recept |
Distribution | u ljekarni |
ATC Code | J07BN01 |
Medicinal product marketed in the Croatia | Da |
Summary of product characteristics (SmPC), labelling and package leaflet (PL) | download |
Link to the European Medicines Agency's (EMA) product information | download |
Link to the European Commission's (EC) decisions | download |
Direct Healthcare Professional Communication
Name | Date | Download |
---|---|---|
Pismo zdravstvenim radnicima o riziku od miokarditisa i perikarditisa za mRNA cjepiva protiv bolesti COVID-19 Comirnaty i Spikevax | 19.07.2021 | BioNTech Manufacturing/Pfizer Croatia d.o.o., Moderna Biotech Spain, S.L. |
Pismo zdravstvenim radnicima o ažuriranju roka valjanosti za cjepivo protiv bolesti COVID-19 Comirnaty - veljača 2022. | 07.02.2022 | BioNTech Manufacturing/Pfizer Croatia d.o.o. |
Pismo zdravstvenim radnicima o ažuriranju roka valjanosti za cjepivo protiv bolesti COVID-19 Comirnaty | 29.09.2021 | BioNTech Manufacturing/Pfizer Croatia d.o.o. |